A Phase I/II Trial of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Mifepristone for Patients With Metastatic Castration Resistant Prostate Cancer (CRPC)
Phase of Trial: Phase I/II
Latest Information Update: 15 Jan 2018
At a glance
- Drugs Enzalutamide (Primary) ; Mifepristone
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 09 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Aug 2018.
- 09 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Jul 2018.
- 10 Jun 2017 Biomarkers information updated